Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Monalizumab · IPH2201, HUMZ270

Monoclonal antibody · Antagonist of NKG2A (killer cell lectin-like receptor C1) (KLRC1) · developed by MedImmune LLC

Phase 3 Most advanced trial
AZN Developer
2 Registered trials

What is Monalizumab?

Monalizumab is a humanized IgG4 monoclonal antibody that binds the inhibitory receptor NKG2A on natural killer cells and T lymphocytes, blocking its interaction with HLA-E on tumor cells. This releases NK and CTL cytotoxic activity against cancer cells. It is being studied in squamous cell carcinoma of the head and neck and of the oral cavity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IPH2201, HUMZ270
Drug type
Monoclonal antibody
Targets
NKG2A (killer cell lectin-like receptor C1) (KLRC1), HLA-E (binding partner it blocks)
Mechanism
Antagonist of NKG2A (killer cell lectin-like receptor C1) (KLRC1)
Pathways
NK cell and CTL cytotoxicity, HLA-E/NKG2A inhibitory signaling
Therapy area
Oncology
Developer
MedImmune LLC (AZN)
Also in trials of
IPHA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
3ZXZ2V0588

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04590963 Phase 3 Squamous Cell Carcinoma of the Head and Neck Active not recruiting IPHA
NCT02331875 Phase 1/2 Squamous Cell Carcinoma of the Oral Cavity Terminated IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the Oral Cavity

Other drugs acting on KLRC1

More from MedImmune LLC

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Monalizumab

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.